Group sales growth: Low to mid single digit.
EPS growth: Broadly in line with sales growth
Half Year 2020
Pharmaceuticals division contributes 79% of total sales.
* CER = Constant Exchange Rate
Half year sales decrease vs HY 2019 mainly due to biosimilar impact - CHF1.7b and unfav forex -CHF1.6b, offset by new products launch +CHF2.5b.
Sales by country/ regions:
Operating margin remained strong 40.2 % of sales.
No comments:
Post a Comment